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Abstract
Background—Convergent evidence suggests that oxidative stress plays a central role in the
pathology of Alzheimer’s disease (AD). We asked if consequently, oxidation of methionine
residues to methionine sulfoxide (MetO) increased in plasma proteins of persons carrying familial
AD (FAD) mutations.
Methods—Plasma was collected from 31 persons from families harboring PSEN1 or APP
mutations. Using Western blot analysis with a novel anti-MetO polyclonal antibody, MetO levels
were measured and compared between FAD mutation carriers (MCs) and non-mutation carrying
(NCs) kin.
Results—A MetO-positive 120 kDa gel band distinguished FAD MCs and NCs (mean 11.4 ± 2.8
vs. 4.0 ± 3.1, p = 0.02). In a subset of subjects for whom both measurements were available, MetO
levels correlated well with plasma F2-isoprostane (r = 0.81, p < 0.001) and superoxide dismutase 1
(r = 0.52, p = 0.004) levels.
Conclusion—Our data provide evidence for elevated MetO levels in persons carrying FAD
mutations that correlate with other indices of oxidative stress and suggest that plasma oxidative
stress markers may be useful for diagnosis of AD.
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Oxidative stress in the brains of persons with Alzheimer’s disease (AD) plays a central role
in propagating [1], or even initiating [2] the illness. Free radicals and reactive oxygen
species (ROS) can overwhelm endogenous antioxidant defenses and damage cellular
components including proteins, lipids, and DNA [1,3,4]. Oxidized forms of these molecules
can be measured in biological fluids and serve as an index of the level of oxidative stress
present [5]. Thus, increased levels of oxidative stress have been found in the brain, CSF, and
plasma of persons with late-onset AD [6].
Familial AD (FAD) is a relatively rare form of AD in which persons inheriting pathogenic
mutations in the PSEN1, PSEN2, or APP genes are destined to develop AD at a relatively
young age. Such mutations are thought to cause the disease through absolute or relative
increase in the amount of the 42-amino acid long form of amyloid β-protein (Aβ42), a
proteolytic cleavage product of amyloid β-protein precursor (APP). Though minor
phenotypic differences exist between typical sporadic AD and certain cases of FAD [7], for
the most part, similar mechanisms are thought to underlie the pathology in FAD and
sporadic AD, including oxidative stress [8,9]. Previously, Ringman et al. reported that F2-
isoprostanes were elevated in the CSF and plasma of persons carrying PSEN1 and APP
mutations [10], suggesting a role for oxidative stress in FAD that may therefore represent a
process that is downstream from Aβ42. F2-isoprostanes are products of nonenzymatic, free-
radical catalyzed peroxidation of arachidonic and docosahexanoic acids, which can be used
as biomarkers, and also are mediators of oxidative stress [11]. Recently, CSF levels of F2-
isoprostanes, though not other disease biomarkers, were found to decrease in response to
antioxidant treatment in Subjects with mild to moderate AD [12].
Non-enzymatic oxidation of methionine residues is a common ROS-induced post-
translational modification of proteins indicative of oxidative damage [13]. Methionine-
sulfoxide reductases (Msr) are enzymes that serve as an endogenous correction mechanism
to reverse such protein oxidation [14]. Msr levels are lower in post mortem AD brain than in
aged-matched control brain [15]. In contrast, higher levels of Msr activity have been found
in a double-transgenic mouse model of AD compared to wild-type mice [16], suggesting
that upregulation of Msr in early stages of AD may be a protective mechanism against
oxidative stress, which fails at late stages as the disease progresses.
Recently, using a novel antibody specific for methionine sulfoxide (MetO)-containing
proteins, Oien et al. have shown an increase in MetO in the serum of a small number of
persons diagnosed with AD compared to age-matched healthy individuals [17]. Following




Plasma was collected from 31 persons from families harboring PSEN1 or APP mutations.
All subjects underwent in-depth clinical, imaging, and biochemical assessments. Twenty-
three subjects were from 10 families with known PSEN1 mutations (A431E substitution
[18,19], n = 8; G206A substitution [20], n = 1; S212Y substitution [21], n = 1) and 8 were
from 2 families harboring APP mutations (both V717I [22]) (Table 1).
The Clinical Dementia Rating Scale (CDR) [23] was performed with an unrelated informant
and the subject, with scores of 0.5, 1, 2, and 3 representing questionable, mild, moderate,
and severe stages of dementia, respectively (Table 1). A sum of boxes (SOB) score also was
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calculated as an index of disability with a wider range. In all but four demented subjects and
two subjects who had undergone clinical presymptomatic testing, ratings were performed
blind to subjects’ genetic status. Subjects were informed they would be tested for APOE
genotype and the FAD mutation for which they were at-risk but in the context of the
research protocol, would not be told the result. All subjects signed written, informed
consent. All study procedures were approved by the Institutional Review Board at UCLA.
Age-of-onset of disease in FAD can be consistent within, but vary between families [18,24].
Therefore, to compare subjects relative to the expected onset of clinical disease, their ages
relative to the median age of disease diagnosis in their families was calculated and
designated “adjusted age” (Table 1).
Genetic testing
DNA was extracted and Apolipoprotein E genotyping performed using standard techniques.
Presenilin-1—The presence of the A431E substitution in PSEN1 was assessed using
restriction fragment length polymorphism analysis. The subject carrying the S212Y PSEN1
mutation was ascertained using a commercial test where the open reading frame of the
coding region of the PSEN1 gene was sequenced. The presence or absence of the G206A
substitution in PSEN1 was assessed directly with bi-directional sequencing.
APP—The presence of the V717I substitution in APP was assessed with direct sequencing.
Blood Collection
Blood was drawn in the morning in a fasting state. Thirty cubic centimeters of plasma were
centrifuged, aliquotted into 0.5-cc siliconized polypropylene Eppendorf tubes, and stored at
−80°C within 2 hours of being drawn. Plasma samples were coded using unique identifiers
and stored at −80°C.
Western blot measurement of MetO
The amount of protein in each sample was measured using a standard BCA protein assay
(Bio-Rad, Hercules, CA). Then, 50 ng protein were mixed with glycine sample buffer
(Invitrogen, Carlsbad, CA) containing 5% β-mercaptoethanol, and fractionated by SDS-
PAGE using 4–20% gradient Tris-glycine gels (Invitrogen). The proteins then were
transferred to nitrocellulose membranes (Invitrogen), blocked using ECL blocking reagent
(Amersham-GE Healthcare, Piscataway, NJ) and incubated with an anti-MetO polyclonal
antibody, which had been raised against oxidized methionine-rich zein protein (anti-MetO-
DZS18) [17]. The membranes were washed, incubated with a goat anti-rabbit secondary
antibody, washed again, and developed by enhanced chemiluminescence (Amersham-GE
Healthcare). Images were recorded using an AlphaImager HP system (Cell Biosciences,
Santa Clara, CA). MetO-reactive bands were quantified densitometrically using ImageJ
(available at http://rsbweb.nih.gov/ij/) and normalized to the entire lane. Samples from each
subject were analyzed in 4 independent experiments and the data averaged.
Isoprostane measurement
A subset of subjects (n = 15) had plasma F2-isoprostane levels measured. Samples were
spiked with internal standard d4-8,12-iso-iPF2α-VI (F2-isoprostanes, or iPF2a) and
extracted on a C18 cartridge column. The eluate was purified by thin-layer chromatography.
The trimethylsilyl derivative then was made and the samples were assayed by chemical
ionization gas chromatography–mass spectrometry in negative ion mode [25].
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Plasma samples from 30 of the subjects were analyzed by Rules Based Medicine, Inc. who
measured the levels of 77 proteins using multiplex immune assays on a Luminex platform.
Briefly, microspheres were color-coded by varying the ratio of a pair of dyes impregnated
into beads. Each bead set was coated with a reagent specific to the molecules of interest,
allowing the capture and detection of specific analytes. Assays were configured such that a
capture antibody was covalently coupled to the surface of the beads. Following sample
incubation and washes, a fluorescently labeled detection antibody then was bound. The
complexes were analyzed in the Luminex instrument, which passes the beads past a pair of
lasers that detect the reporter dye on the detection antibody and the dye ratio simultaneously.
A total of eight multiplex assays, comprising all 77 target-molecules, were run on each
plasma sample. Each multiplex run included analyte specific standards and controls. Plasma
levels of superoxide dismutase 1 (SOD1) were analyzed for the current paper.
Statistical Analysis
Levels of MetO reactivity (see below) were compared between FAD mutation carriers
(MCs) and non-carriers (NCs) by an independent-samples t-test. Considering the non-
normality of the distribution of MetO reactivity, values were log transformed and the t-test
repeated to confirm the results. MetO reactivity was analyzed for possible interaction with
smoking (smokers vs. non-smokers), gene (APP vs. PSEN1), mutation carrier status (present
or absent), or APOE genotype variables using one-way ANOVA. Additionally, we
examined the combined effect of gene and mutation status on MetO reactivity using two-
way ANOVA. Spearman’s correlations were sought between age, adjusted age, and CDR
SOB score and MetO reactivity for the population as a whole as well as separately for MCs
and NCs. Demographic characteristics were compared between MCs and NCs by t-tests and
χ2 tests as appropriate. Correlations were sought between SOD1, F2-isoprostane, and MetO
reactivity using Spearman correlation.
Results
Of the 31 subjects analyzed, 19 were MCs (PSEN1 = 14, APP = 5) and 12 were NCs.
Among MCs, 12 were asymptomatic (CDR score = 0), 4 had questionable or minor
cognitive impairment (CDR score = 0.5), and one subject each had mild, moderate, and
severe dementia. Subjects did not differ in regard to mean absolute age or adjusted age. We
asked whether markers of oxidative stress, including plasma MetO and isoprostane levels
correlated with the genotype and/or the clinical status of the subjects participating in the
study. In Western blot analysis using a novel anti-MetO antibody, we observed 4 major
bands at 120, 135, 160, and ~200 kDa (Figure 1A). The ~200-kDa band contained several
bands with a wide range of variability. Two independent operators, blinded to mutation
status, were asked to find patterns in the data and reached a consensus dividing the 31
samples into four groups (Figure 1A). Group I (n = 5) was characterized by high mean
abundance of the 120 kDa and low mean abundance of the ~200-kDa band compared to the
other three groups. Group II (n = 6) had the highest mean abundance of the 135-kDa band
and a low abundance of the 120-kDa band. In contrast, groups III (n = 13) and IV (n = 7)
both had low mean abundance of the 135-kDa band. In addition, group IV had a very low
abundance of the 120-kDa band (Figure 1B). The 120-kDa band was the most distinctive
feature among the groups (Figure 1), and therefore was chosen as a criterion for quantitative
analysis of the different patterns observed. To standardize this measure among subjects, the
densitometric value (arbitrary densitometric units) of the 120-kDa band was normalized to
the entire lane and defined as “MetO reactivity,” which was used for comparison among
subjects.
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The MetO reactivity was found to be significantly greater in FAD MCs than NCs (11.4 ± 2.8
vs. 4.0 ± 3.1, p = 0.02) (Figure 2). When the MetO reactivity was log transformed, this
difference was maintained (0.92 vs. 0.57, p = 0.02). Moreover, comparison between the 12
asymptomatic FAD MCs and the NCs showed an even higher difference in MetO reactivity
in the former (13.1 ± 13.8 vs. 4.0 ± 3.1, p = 0.045) and the difference remained significant
when the data were log transformed (p = 0.02). In contrast, there were no significant
relationships between CDR SOB scores, current smoking, age, adjusted age, or mutation
type and MetO reactivity.
The two markers of oxidative stress, MetO reactivity and F2-isoprostane levels showed high
positive correlation, r = 0.80 (p < 0.001, Figure 3). Interestingly, we also found positive
correlation between MetO reactivity and plasma levels of SOD1 (r = 0.62, p < 0.001, Figure
4).
Discussion
Our Western blot analysis using a novel anti-MetO antibody showed four different patterns
among the 31 patients. The anti-MetO antibody recognizes MetO residues depending on
their exposure on the protein surface. Previously, it was shown that oxidation of Met to
MetO may cause major conformational rearrangements leading to exposure of Met residues
that are buried in their native, reduced form [26]. It is difficult, however, to predict whether
this happens in every specific epitope. Thus, the antibody is believed to be specific to the
sulfoxide group of MetO [17], but deciphering the specific binding epitope in a protein of
interest will need to be addressed in future studies.
In particular, we found elevated MetO reactivity, measured densitometrically in a 120-kDa
band using an anti-MetO antibody (Figure 1), in persons carrying FAD mutations. This
effect appeared to be driven largely by five the FAD mutation carriers in group I, who had
high MetO reactivity (Figures 1B and 2). Of these persons, four carried a PSEN1 A431E
mutation and one carried an APP V717I mutation. Notably, all non-carriers had low MetO
reactivity and the only 3 subjects for whom MetO reactivity was below detectable levels
were non-carriers. Thus, the presence of a prominent 120-kDa band in our assay correlated
in all cases with an FAD mutation, though the absence of this band did not necessarily
indicated the absence of mutation. The findings suggest that high plasma MetO reactivity
may be indicative of an ongoing disease process accompanied by oxidative stress, which
fails to be mitigated by the Msr system in FAD mutation carriers.
We did not find clear correlations between MetO reactivity and age, adjusted age, or disease
status as 4 of the 5 subjects with the highest MetO reactivity levels were young and
asymptomatic (CDR score of 0) and one had moderate dementia (CDR score of 2). It is
possible that correlations would be found in a larger sample, which was not available for this
study.
The strong positive correlation between MetO reactivity and F2-isoprostanes levels support
the role of oxidative stress in FAD and suggests that although the pathology occurs in the
brain, it is evident also in the periphery in the form of elevated lipid peroxidation
(isoprostanes) and protein oxidation (MetO) markers. Unfortunately, F2-isoprostane levels
were not available for the 5 subjects for whom MetO levels were highest. We therefore
cannot conclude at this point that the correlation found is maintained at such levels.
The positive correlation between MetO reactivity and plasma SOD1 levels is an intriguing
finding. SOD1 is a cytosolic protein and its origin in the plasma of the population studied
here is uncertain. The correlation found may indicate an increase of SOD1 production and
secretion into the plasma as a compensatory response to oxidative stress, or reflect elevated
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enzyme release due to enhanced cell death. SOD1 is a highly stable protein [27], suggesting
that it may have a long half-life [28] compared with other cytoplasmic proteins released
following cell death. SOD1 plays an important role in preventing mitochondrial-linked cell
death [29,30]. Accordingly, oxidative stress may prompt cells to respond by upregulating
SOD1 as a protective mechanism against oxidative damage [31,32]. Failure of this response
mechanism may increase the release of SOD1 through oxidative damage to cellular
membranes.
The finding of increased MetO reactivity in asymptomatic persons carrying FAD mutations
and the correlation between MetO reactivity and other indices of oxidative stress supports an
important role for oxidative stress early in the pathogenesis of FAD. As overproduction of
Aβ42 is thought to be the critical factor causing the disease in persons with FAD-linked
mutations, our findings suggest that though oxidative stress is an early pathologic process in
AD, it occurs downstream of the Aβ-induced neuronal injury.
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Western blot analysis of plasma proteins by anti-MetO antibody. A) MetO-reactive bands
were divided into four groups based on pattern recognition by two investigators blinded to
mutation or disease status. B) Densitometric analysis of the four prominent gel bands
observed.
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Levels of MetO reactivity in FAD mutation carriers and non-carriers quantified
densitometrically (Student’s t-test, p = 0.02).
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Correlation between F2-isoprostane levels and MetO reactivity (Spearman’s correlation, r =
0.81, p < 0.001).
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Correlation between superoxide dismutase 1 levels and MetO reactivity (Spearman’s
correlation, r = 0.52, p = 0.004).
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Table 1
Demographic data.
FAD mutation carriers (n = 19) Non-carriers (n = 12)
Age in years (s.d.) 36.2 (9.7) 38.8 (11.5) p = 0.51i
Adjusted age (s.d.) −9.1 (10.4) −6.8 (15.9 p = 0.65i
CDR sum of boxes score 2.5 (5.2) 0.3 (0.3) p = 0.08i
Gender, # female (%) 14 (74%) 9 (75%) p = 1.00ii
Gene mutated in family APP = 5, PSEN1 = 14 APP = 3, PSEN1 = 9 p = 1.00ii
APOE genotype, # 2/3, 3/3, 3/4 5, 11, 3 1, 7, 4 p = 0.33iii
# who smoke* (%) 1 (6%) 5 (42%) p = 0.06ii
i
indicates a two-sided T-test,
ii
 indicates two-sided Fisher’s Exact test,
iii
 indicates Pearson Chi-Square test.
*
Smoking data is missing for 3 subjects
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